Literature DB >> 9014801

Effects of blockade of fast and slow inward current channels on ventricular fibrillation in the pig heart.

A J Stewart1, J D Allen, A B Devine, A A Adgey.   

Abstract

OBJECTIVE: To determine the contribution of fast and slow inward channels to the electrocardiogram (ECG) of ventricular fibrillation.
METHODS: Ventricular fibrillation was induced by endocardial electrical stimulation in pigs anaesthetised with pentobarbitone sodium (30 mg/kg intravenously). ECGs simultaneously recorded from the body surface (lead II) and from the endocardium were studied by power spectrum analysis (0-40 Hz).
RESULTS: The mean (SEM) dominant frequency of fibrillation (9.0 (1.1) Hz in lead II at 0-40 s) did not change significantly with time in pigs given intravenous saline. However, the dominant frequency was significantly reduced by intravenous pretreatment with the class I antiarrhythmic drugs, lignocaine (3 mg/kg, 6.5 (0.5) Hz; 10 mg/kg, 4.2 (0.6) Hz), mexiletine (3 mg/kg, 6.2 (0.4) Hz; 10 mg/kg, 5.5 (0.4) Hz), and disopyramide (2.5 mg/kg, 5.4 (0.6) Hz). After flecainide (3 mg/kg, 6.9 (0.5) Hz) the reduction in frequency was not significant. Similar data were obtained with endocardial recordings. In contrast pre-treatment with verapamil (0.2 mg/kg, 11.7 (0.8) Hz; and 1.0 mg/kg, 12.9 (1.6) Hz) produced a significantly higher dominant frequency of fibrillation than saline and widened the bandwidth of frequencies around the dominant frequency.
CONCLUSIONS: These results indicate that voltage-dependent sodium channel currents contribute to the rapid frequencies of ventricular fibrillation. Blockade of L-type inward calcium channel activity increases the fibrillation frequency and fractionates the frequencies of the fibrillation wavefronts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9014801      PMCID: PMC484605          DOI: 10.1136/hrt.76.6.513

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  36 in total

Review 1.  Electrophysiology and pharmacology of cardiac arrhythmias. V. Cardiac antiarrhythmic effects of lidocaine.

Authors:  M R Rosen; B F Hoffman; A L Wit
Journal:  Am Heart J       Date:  1975-04       Impact factor: 4.749

Review 2.  Mechanisms underlying ventricular tachycardia and fibrillation in the ischemic heart: relation to nonlinear dynamics.

Authors:  S M Pogwizd; P B Corr
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

3.  Analysis of the body surface ECG measured in independent leads during ventricular fibrillation in humans.

Authors:  R H Clayton; A Murray; R W Campbell
Journal:  Pacing Clin Electrophysiol       Date:  1995-10       Impact factor: 1.976

4.  Is fibrillation chaos?

Authors:  D T Kaplan; R J Cohen
Journal:  Circ Res       Date:  1990-10       Impact factor: 17.367

5.  Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation.

Authors:  J C Merillat; E G Lakatta; O Hano; T Guarnieri
Journal:  Circ Res       Date:  1990-11       Impact factor: 17.367

6.  Calcium inhibition of glycolysis contributes to ischaemic injury.

Authors:  W Auffermann; S Wagner; S Wu; P Buser; W W Parmley; J Wikman-Coffelt
Journal:  Cardiovasc Res       Date:  1990-06       Impact factor: 10.787

7.  Nature of [Ca2+]i transients during ventricular fibrillation and quinidine treatment in perfused rat hearts.

Authors:  S Kojima; J Wikman-Coffelt; S T Wu; W W Parmley
Journal:  Am J Physiol       Date:  1994-04

8.  Frequency analysis of ventricular fibrillation and resuscitation success.

Authors:  A J Stewart; J D Allen; A A Adgey
Journal:  Q J Med       Date:  1992-10

9.  Effects of verapamil and Bay K 8644 on defibrillation energy requirements in dogs.

Authors:  R Schräder; M Brooks; D S Echt
Journal:  J Cardiovasc Pharmacol       Date:  1992-06       Impact factor: 3.105

10.  Changes in the surface electrocardiogram during the onset of spontaneous ventricular fibrillation in man.

Authors:  R H Clayton; A Murray; R W Campbell
Journal:  Eur Heart J       Date:  1994-02       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.